GTx investors powered up over US FDA nod for Phase III muscle wasting trials
This article was originally published in Scrip
Executive Summary
Investors embraced the news on 6 June that GTx had come to an agreement with the US FDA for the firm's two Phase III registration studies testing its oral selective androgen receptor modulator Ostarine as a therapy to prevent and treat muscle wasting in patients with non-small-cell lung cancer (NSCLC) by pushing shares of the Memphis, Tennessee company up as high as 7.8%, or 46 cents, before closing at $6, a gain of 11 cents.